OSR Holdings, a global healthcare company dedicated to advancing biomedical innovation, recently provided a transparency update on its Equity Line of Credit (ELOC) agreement. CEO Peter Hwang emphasized that while financing mechanisms like ELOCs carry dilution risk, the proceeds are directly invested in accelerating development across drug R&D, medical devices, and digital asset ecosystems. With less than 10% of registered shares issued under the ELOC, OSRH is committed to aligning financing activities with growth objectives to protect shareholder value.
The company’s current share price, according to Hwang, does not reflect its intrinsic value, which includes strategic moves like acquiring noninvasive glucose monitoring technology through a partnership with Woori IO. This partnership, involving a clinical trial in Korea with a leading technology company, highlights OSRH’s dedication to innovative healthcare solutions. OSR Holdings, through its subsidiaries, focuses on immuno-oncology, regenerative biologics, and medical device distribution, aiming to improve patient care through cutting-edge research and development.
Read more on finance.yahoo.com